2013-06-22 19:32:51 - New Pharmaceuticals market report from GlobalData: "PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis"
GlobalData has released its new Country report, "PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis". Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck's Victrelis (boceprevir) or Vertex's Incivek
(telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.
Full Report Details at
- www.fastmr.com/prod/623152_pharmapoint_hepatitis_c_virus_germany ..
GlobalData expects that factors such as HCV screening initiatives, increases in patient awareness, and the launch of next-generation HCV therapies will drive the growth of the HCV market in Germany.
Incivo was among the first DAA HCV regimens launched in German. The drug quickly captured market share due to its improved efficacy over the previous standard of care, a combination of peginterferon and ribavirin, for the most prevalent HCV genotype in Germany, HCV GT1. GlobalData believes that Incivo's shorter duration of triple therapy (i.e., co-administration of DAA, peginterferon, and ribavirin) enabled it to capture more market share than Merck's Victrelis, the other DAA launched around the same time as Incivo.
* Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in Germany from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting Germany HCV market.
Reasons to Get this Report
* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for HCV
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2022 in Germany
Partial Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
4 Disease Management
4.1 Diagnosis and Referral Overview
4.2 Treatment Overview
4.3.2 Clinical Practice
5 Competitive Assessment
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 Incivek (telaprevir)
5.3.2 Victrelis (boceprevir)
5.3.3 Pegasys (peginterferon alfa-2a)
5.3.4 PegIntron (peginterferon alfa-2b)
5.3.5 Copegus, Rebetol, and Generic Ribavirin
5.3.6 Therapeutic Class: Interferon
6 Opportunity and Unmet Need
6.2 Unmet Needs
6.2.1 Unmet Need: Treatment Tolerability
6.2.2 Unmet Need: Efficacy
6.2.3 Unmet Need: Disease Awareness
6.2.4 Unmet Need: Treatment Cost
6.2.5 Unmet Need: Shorter Treatment Duration
6.2.6 Unmet Need: Simplified Treatment Regimens
6.3 Unmet Needs Gap Analysis
6.4.1 Opportunity: Pan-genotypic HCV Regimen
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations
6.4.3 Opportunity: Involvement of Immune System
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
7.2.1 Sofosbuvir and Sofosbuvir/Ledipasvir
7.2.3 ABT-450 plus ABT-267 and ABT-333
7.2.4 Faldaprevir and Faldaprevir plus BI 207127
7.2.5 Daclatasvir and Daclatasvir plus Asunaprevir
7.2.6 Other Drug Classes
8 Market Outlook
8.1.2 Key Events
8.1.3 Drivers and Barriers
9.4 Forecasting Methodology
9.4.1 Percent Drug-Treated Patients
9.4.2 Patient Warehousing
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Selection of Pipeline Agents
9.4.9 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 Survey of Prescribing Physicians
Full Table of Contents is available at:
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.